Elsevier

The Lancet Oncology

Volume 22, Issue 10, October 2021, Pages 1355-1357
The Lancet Oncology

Comment
Surgery versus SABR for early-stage lung cancer—time to call it a draw?

https://doi.org/10.1016/S1470-2045(21)00457-5Get rights and content

First page preview

First page preview
Click to open first page preview

References (10)

There are more references available in the full text version of this article.

Cited by (5)

  • Stereotactic Ablative Radiotherapy in the Treatment of Early-Stage Lung Cancer – A Done Deal?

    2022, Clinical Oncology
    Citation Excerpt :

    Subsequently, the STARS trial was revised with re-accrual of the SABR arm to a larger sample size, which was then compared to a propensity-matched surgically managed cohort [21]. This is well-described in another recent review article [22]. The median follow-up was 5.1 years and survival outcomes were similar between the SABR and surgery group [21].

  • Cytofluorometric assessment of cell cycle progression in irradiated cells

    2022, Methods in Cell Biology
    Citation Excerpt :

    Radiation therapy (RT) is one of the regimens most commonly employed in modern clinical cancer care, either as a curative intervention (e.g., in patients with early-stage prostate cancer) (Harmenberg et al., 2011; Nakano et al., 2010), or to palliate symptoms from metastatic disease (e.g., pain) (Spencer et al., 2018). Technological progress achieved over the past two decades has enabled the delivery of high RT doses to ever more precise target volumes along with minimal exposure of normal tissues, considerably expanding the clinical applications or RT (Citrin, 2017; Deutsch et al., 2019; Louie et al., 2021; Salama et al., 2012; Siva et al., 2017; Zaorsky et al., 2013). RT largely operates by directly or indirectly (via reactive oxygen species) (Li et al., 2021a; Renaudin, 2021) causing damage to macromolecules, including DNA (Pilié et al., 2019) and lipids (Lei et al., 2020; Ye et al., 2020).

View full text